SPEAKER | Raju Kucherlapati, Ph.D., President, Paul C. Cabot Professor of Genetics, Harvard Medical School

With entire nations in the throes of the Covid- 19 pandemic in 2020, Siddhartha Mukherjee urged researchers to count viral spread “within people” as well as “across peoples.” The “science of aggregation,” he explained in an essay published by The New Yorker on April 6, 2020, is most effective when it moves in step with “the science of the one.” During this opening keynote presentation, the globally renowned author of The Emperor of All Maladies and The Gene: An Intimate History will provide an update on his thinking about the status and outlook for personalized medicine in a post-pandemic world.

KEYNOTE SPEAKER | Siddhartha Mukherjee, M.D., D.Phil., Assistant Professor of Medicine, Columbia University

Game-changing early detection. Pre-screening for genetic risk factors. In the era of personalized medicine, biomarker-based cancer diagnostics are captivating the public imagination based on their potential to help physicians get ahead of the second-leading cause of death in the United States. Against this backdrop, a test developer, a patient advocate, a representative from a leading cancer center, and a medical geneticist will discuss strategies for communicating with patients about the complexities of the “dreaded disease.”

MODERATOR | TBD

Kevin Conroy, Chairman, CEO, Exact Sciences

Robert C. Green, M.D., Professor of Medicine, Harvard Medical School; Co-Founder, Scientific Advisory Board Chair, Genome Medical

Sapna Syngal, M.D., Strategic Planning Director, Prevention and Early Cancer Detection, Dana Farber Cancer Institute

TBD

Sponsored by

In 2021, a steering committee of patients and patient advocates came together to support the launch of a Personalized Medicine Coalition educational platform that encourages patients to advocate for health care tailored not only to their biological characteristics, but also to their circumstances and values. The online resource promises to broaden public understanding of what it means to personalize health care. During this panel discussion, the nationally recognized patient advocates leading the More Than a Number initiative will discuss the importance of enhancing patient-provider interactions with attention to the full scope of biological, environmental, and social factors that impact the health and well-being of every individual.

MODERATOR | Faswilla Sampson, Chief Operating Officer, Personalized Medicine Coalition

Deanna Darlington, President, Links2Equity

Candace Henley, Founder, Blue Hat Foundation

Sarah Krüg, Executive Director, Cancer101

The Annual Award for Leadership in Personalized Medicine recognizes an individual whose contributions in science, business, and policy have helped advance the frontiers of the field. This year’s award goes to pioneering genomics researcher Geoffrey Ginsburg. Long recognized by his colleagues as a founder and luminary, Dr. Ginsburg’s work emphasizes the importance of translating emerging discoveries in genomics and personalized medicine into improved health outcomes for all patients. In November of 2021, the National Institutes of Health selected Dr. Ginsburg as the Chief Medical and Scientific Officer of the All of Us Research Program, a flagship initiative in personalized medicine distinguished for its emphasis on diversity and inclusion.

PRESENTER | Jay G. Wohlgemuth, M.D., Chief Medical Officer, Senior Vice President, Quest Diagnostics

AWARDEE | Geoffrey Ginsburg, M.D., Ph.D., Chief Medical and Scientific Officer, All of Us Research Program, U.S. National Institutes of Health

Personalized medicine calls for a more diverse, equitable, and inclusive biomedical research enterprise that can provide reliable evidence about the ways in which various health care interventions may affect subsets of heterogenous patient populations. It also calls for clinical interactions tailored more closely to patients’ circumstances, preferences, and cultural backgrounds. During this panel discussion, a diverse group of health care leaders will explain how a focus on personalized medicine will improve patient care.

MODERATOR | James W. Lillard, Ph.D., Senior Associate Dean, Morehouse School of Medicine

Donna R. Cryer, J.D., President, CEO, Global Liver Institute

TBD

TBD

Prior authorization. Informed consent. And, too often, a diagnostic odyssey. The complexities of the health care system can be exasperating. During this panel discussion, a caregiver, a payer, a pharmaceutical industry representative, and a health system administrator will discuss strategies for ensuring patient access to high-quality health care tailored to each patient’s needs.

MODERATOR | Alan Balch, Ph.D., CEO, National Patient Advocate Foundation

J. Michael Graglia, Co-Founder, Managing Director, SynGAP Research Fund

Tammy McAllister, Operations Administrator, Center for Individualized Medicine, Mayo Clinic

John M. O’Brien, Pharm.D., President, CEO, National Pharmaceutical Council

Susan Perry, Head of Strategy and Operations, Office of the Chief Medical Officer, Point32Health

In October of 2019, Dr. Timothy Yu of Boston Children’s Hospital co-authored a landmark paper in The New England Journal of Medicine reporting the successful administration of an “n-of-one” therapy specially designed for Mila Makovec, an eight-year-old patient with an ultra-rare neurological disorder. The development of the therapy points to the rapidly expanding possibilities in personalized medicine. It also raises questions about how to regulate and pay for n-of-one therapies in the future. During this fireside chat, Mila’s mother will join Dr. Yu to reflect on their experiences and consider the future of personalized medicine for patients with rare diseases.

MODERATOR | Walter Kowtoniuk, Ph.D., Venture Partner, Third Rock Ventures

Julia Vitarello, mother of the late Mila Makovec; CEO, Mila’s Miracle Foundation; Co-Founder, N=1 Collaborative

Timothy Yu, M.D., Ph.D., Staff Physician & Investigator, Division of Genetics and Genomics, Boston Children’s Hospital; Co-Founder, N=1 Collaborative

During this panel discussion on the future of pharmacogenomics, a patient harmed by severe side effects from an antibiotic will reflect on the shortcomings of one-size-fits-all prescribing practices; a provider of pharmacogenetic testing services will review data from a pilot program showing the clinical and economic advantages of selecting and dosing drugs based on each patient’s genetic characteristics; and the executive director of precision health at a leading health system will identify the obstacles still slowing the uptake of pharmacogenetic testing in clinical settings.

MODERATOR | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

Rachel Brummert, Patient Advocate; Communications Lead, American Society of Pharmacovigilance

Howard McLeod, Pharm.D., Executive Clinical Director, Precision Health, Intermountain Healthcare

TBD

When Karen Tumulty, a longtime political correspondent for The Washington Post, was diagnosed with multiple myeloma, the experience changed her thinking about health care in America. During this wide-ranging fireside chat with the Founder of the Multiple Myeloma Research Foundation, Tumulty, who now serves as The Washington Post’s Deputy Editorial Page Editor, will reflect on her experiences as a patient and share her views on what the midterm elections may mean for the future of health care and personalized medicine.

MODERATOR | Kathy Giusti, Founder, Chief Mission Officer, Multiple Myeloma Research Foundation

Karen Tumulty, Deputy Editorial Page Editor, The Washington Post

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition